The eighth edition of the tumor-node-metastasis (TNM) classification classified stage III non-small cell lung cancer in sub-stages IIIA, IIIB, and IIIC. There is no further subclassification but Stage IIIA represents already a heterogeneous group of lung cancers invading chest wall/mediastinal organs or with concomitant N2 disease. This heterogeneity poses a tremendous challenge for surgeons, oncologists, radiation-oncologist involved in the management of patients with Stage IIIA disease. This series is a comprehensive overview about management of stage IIIA lung cancer by leading experts internationally recognized.
Controversies in the management of stage IIIa non-small-cell lung cancer
Heterogeneity of stage IIIA non-small cell lung cancer—different tumours, different nodal status, different treatment, different prognosis: a narrative review
Management of stage IIIA non-small-cell lung cancer: role of surgery
Management of stage IIIA non-small cell lung cancer (NSCLC): role of the chemotherapy
Management of stage IIIA NSCLC: the role of radiotherapy—a narrative review
Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review
Stage IIIA non-small cell lung cancer: a contraindication for video-assisted thoracic surgery lobectomy?—a narrative review
Management of stage IIIA non-small cell lung cancer in elderly patients: should we do differently?—a narrative review
Narrative review of the management of stage IIIA non-small cell lung cancer: does different management equal different quality of life?
Persistent N2 disease after neoadjuvant treatment...and now?—The oncologist view
Disclosure:
The series “Controversies in the Management of Stage IIIA Non-Small-Cell Lung Cancer” was commissioned by the editorial office, Current Challenges in Thoracic Surgery without any sponsorship or funding. Fabrizio Minervini and Marco Scarci are serving as the unpaid Guest Editors for the series.